1992 related articles for article (PubMed ID: 15867204)
21. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
22. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
23. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
24. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
[TBL] [Abstract][Full Text] [Related]
26. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
Samaras P; Heider H; Haile SR; Petrausch U; Schaefer NG; Siciliano RD; Meisel A; Mischo A; Zweifel M; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2010 Aug; 89(8):783-7. PubMed ID: 20204361
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
Ueda K; Yokoyama M; Asai H; Koudaira M; Yamada S; Katsube A; Mishima Y; Sakajiri S; Takeuchi K; Saotome T; Terui Y; Takahashi S; Hatake K
Gan To Kagaku Ryoho; 2010 May; 37(5):853-7. PubMed ID: 20495315
[TBL] [Abstract][Full Text] [Related]
28. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
30. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953
[TBL] [Abstract][Full Text] [Related]
31. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
32. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
[TBL] [Abstract][Full Text] [Related]
33. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
34. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma.
Morrison VA
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1651-8. PubMed ID: 18925856
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
Shen Y; Yao Y; Li JM; Chen QS; You JH; Zhao HJ; Chen S; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):252-7. PubMed ID: 18843980
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
[TBL] [Abstract][Full Text] [Related]
37. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
[TBL] [Abstract][Full Text] [Related]
38. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
39. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma.
Tholstrup D; de Nully Brown P; Jurlander J; Hansen M
Eur J Haematol; 2007 Aug; 79(2):100-6. PubMed ID: 17608712
[TBL] [Abstract][Full Text] [Related]
40. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]